XML 45 R18.htm IDEA: XBRL DOCUMENT v3.25.2
Shareholders' Deficit
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2023
Shareholders' Deficit [Abstract]    
Stockholders' Equity, Policy [Policy Text Block]  
Warrants
In fiscal year 2020, in conjunction with our issuance of our 12% Senior Secured Notes due 2025, which we subsequently redeemed in fiscal year 2021, we also issued 7-year warrants to purchase 1,055,377 ordinary shares of Cimpress, representing approximately 3.875% of our outstanding diluted ordinary shares at the time of issuance. The warrants, which currently remain outstanding, are accounted for as equity, as they are redeemable only in our own shares, with an exercise price of $60 per share. The warrants may be exercised by cash payment or through cashless exercise by the surrender of warrant shares having a value equal to the exercise price of the portion of the warrant being exercised.
The fair value used for the warrants in this allocation was calculated using the Monte Carlo valuation model. The valuation of the notes and warrants resulted in a carrying value allocated to the warrants of $22,432, which, in addition to being accounted for as an equity instrument recorded in additional paid in capital, was included as a discount to the 12% Senior Secured Notes.
Share-based awards

On November 25, 2020, our shareholders approved our 2020 Equity Incentive Plan (the "2020 Plan"). Upon approval, we ceased granting new awards under any of our prior equity plans – the 2016 Performance Equity Plan, 2011 Equity Incentive Plan, and 2005 Non-Employee Directors' Share Option Plan, and we now grant all equity awards under the 2020 Plan. Some awards previously granted under the former plans remain outstanding and are governed by their original terms.

The 2020 Plan allows us to grant share options, share appreciation rights, restricted shares, restricted share units, other share-based awards, and dividend equivalent rights to our employees, officers, non-employee directors, consultants, and advisors. The maximum number of ordinary shares authorized for issuance under the 2020 Plan is 7,500,000, plus an additional number of shares equal to the number of PSUs outstanding under the 2016 Performance Equity Plan that expire, terminate, or are otherwise surrendered, canceled, or forfeited.
As of June 30, 2025, 2,211,747 ordinary shares were available for future awards under our 2020 Plan. For PSUs where the performance condition has not been completed, we assumed that we would issue the maximum potential ordinary shares based on the terms described below.
Performance share units
During the prior fiscal year, we issued PSUs (the "2024 PSUs") as part of our long-term incentive program. The 2024 PSUs include both a service and performance condition. The performance condition for these awards was based on one-year financial targets for fiscal year 2024 revenue, adjusted EBITDA, and unlevered free cash flow. Actual shares issued for each grant could range from 0% to 160% of the number of 2024 PSUs granted based on the attainment of the performance condition.
During the current fiscal year, we issued PSUs (the "2025 PSUs") as part of our long-term incentive program. The 2025 PSUs include both a service and performance condition. The performance condition for these awards is based on one-year financial targets for fiscal year 2025 revenue, adjusted EBITDA, and unlevered free cash flow. On May 23, 2025, the Compensation Committee of Cimpress' Board of Directors amended the terms of the 2025 PSUs to incorporate a minimum performance attainment of 60%, subject to the Compensation Committee's discretion to account for non-recurring items, that previously had been 0%. The change of terms impacted all 276 PSU grant recipients for the 2025 PSUs with awards outstanding as of the modification date. The modification resulted in incremental compensation expense of $4.8 million from the awards for which estimated attainment as of the modification date was below 60%. Actual shares issued for each grant will range from 60% to 160% of the number of 2025 PSUs granted based on the attainment of the performance condition, subject to the Compensation Committee's discretion to account for non-recurring items. The final measurement of the performance condition will occur during the first quarter of fiscal year 2026.
All other outstanding PSUs entitle the recipient to receive Cimpress ordinary shares between 0% and 250% of the number of units, based upon service vesting requirements and the achievement of a compounded annual growth rate target based on Cimpress' three-year moving average share price. PSU awards with a grant date prior to fiscal year 2020 and PSU awards granted before fiscal year 2025 to our Chief Executive Officer and Board of Directors are assessed for achievement annually in years 6 - 10 following the grant date and awards with a grant date in or after fiscal year 2020 and before fiscal year 2025 (other than to the CEO and Board) will be assessed annually for achievement in years 4 - 8 following the grant date.
A summary of our PSU activity and related information for the fiscal year ended June 30, 2025 is as follows:
PSUsWeighted-
Average
Grant Date Fair
Value		Aggregate
Intrinsic
Value
Outstanding at the beginning of the period1,934,853 $109.48 
Granted685,291 80.80
Vested and distributed(324,909)70.22 
Forfeited(34,776)76.51
Outstanding at the end of the period2,260,459 $106.93 $106,242 
The weighted average fair value of PSUs granted during the fiscal years ended June 30, 2025, 2024, and 2023 was $80.80, $70.21, and $17.61, respectively. The total intrinsic value of PSUs outstanding as of June 30, 2025, 2024, and 2023 was $106,242, $169,512, and $83,376, respectively. The total intrinsic value of PSUs assumes that the performance condition is met at target; however, it is possible that a portion or all of these PSUs granted before fiscal year 2024 will not achieve the associated market condition. As of June 30, 2025, the number of shares subject to PSUs included in the table above assumes the issuance of one share for each PSU, but based on the terms of each program as described above, the actual issuance of shares could range from a minimum of 685,084 shares to a maximum of 4,623,522 shares.
Restricted share units

    The fair value of an RSU award is equal to the fair market value of our ordinary shares on the date of grant and the expense is recognized on a straight-line basis over the requisite service period. RSUs generally vest over 4 years.
A summary of our RSU activity and related information for the fiscal year ended June 30, 2025 is as follows:
RSUsWeighted-
Average
Grant Date Fair
Value		Aggregate
Intrinsic
Value
Unvested at the beginning of the period1,103,713 $62.59 
Granted377,492 83.71
Vested and distributed(538,975)65.61 
Forfeited(76,349)62.84
Unvested at the end of the period865,881 $69.89 $40,696 
The weighted average fair value of RSUs granted during the fiscal years ended June 30, 2025, 2024, and 2023 was $83.71, $71.42, and $44.25, respectively. The total intrinsic value of RSUs vested during the fiscal years ended June 30, 2025, 2024, and 2023 was $38,110, $47,661, and $13,544, respectively.
Share options
We have granted options to purchase ordinary shares at prices that are at least equal to the fair market value of the shares on the date the option is granted and that generally vest over four years with a contractual term of ten years.
The fair value of each option award subject only to service period vesting is estimated on the date of grant using the Black-Scholes option pricing model. Use of a valuation model requires management to make certain assumptions with respect to inputs. The expected volatility assumption is based upon historical volatility of our share price. The expected term assumption is based on the contractual and vesting term of the option and historical experience. The risk-free interest rate is based on the U.S. Treasury yield curve with a maturity equal to the expected life assumed at the grant date.
We did not grant any share options in fiscal years 2025 or 2024. Weighted-average values used for option awards in fiscal year 2023 were as follows:
Year Ended June 30,
2023
Risk-free interest rate3.06 %
Expected dividend yield— %
Expected term (years)4.01
Expected volatility61.99 %
Weighted average fair value of options granted$22.83 
A summary of our share option activity and related information for the year ended June 30, 2025 is as follows:
Shares Pursuant to OptionsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term (years)		Aggregate
Intrinsic
Value
Outstanding at the beginning of the period338,593 $46.39 7.3$13,956 
Exercised(29,784)46.20 
Forfeited/expired(20,902)52.56
Outstanding at the end of the period287,907 $45.96 7.0$344 
Exercisable at the end of the period200,106 $46.11 7.0$223 
The intrinsic value in the table above represents the total pre-tax amount, net of exercise price, which would have been received if all option holders exercised in-the-money options on June 30, 2025. The total intrinsic value of options exercised during the fiscal years ended June 30, 2025, 2024, and 2023 was $1,318, $1,816 and $41, respectively.
Share-based compensation
Total share-based compensation costs were $58,879, $65,584, and $42,122 for the years ended June 30, 2025, 2024, and 2023, respectively, and we recognize the impact of forfeitures as they occur. Share-based compensation costs capitalized as part of software and website development costs were $3,808, $3,160, and $1,879 for the years ended June 30, 2025, 2024, and 2023, respectively.
For the years ended June 30, 2025, 2024, and 2023, we recognized tax benefits on total share-based compensation costs, as part of income tax expense (benefit) of $10,797, $11,970, and $7,649, respectively. For the years ended June 30, 2025, 2024, and 2023, tax benefit (expense) related to awards vested or exercised was $426, $1,190, and ($2,514), respectively.
As of June 30, 2025, there was $68,370 of total unrecognized compensation cost related to non-vested, share-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.8 years.
Purchase and retirement of ordinary shares
During the year ended June 30, 2025, we repurchased 1,193,355 of our ordinary shares for $77,775. The shares were immediately retired after repurchase and therefore have been classified as authorized and unissued shares as of June 30, 2025. The retirement of the repurchased ordinary shares resulted in a reduction in ordinary shares of $13, as well as a reduction to additional paid in capital and retained earnings of $16,608 and $61,154, respectively.
Shareholders' Equity and Share-based Payments 1,318